Plants are fantastic natural chemists
For decades, tropical plants like kratom and cat's claw quietly harbored a molecular secret — the ability to construct mitraphylline, a rare compound with anti-cancer and anti-inflammatory promise, through a process science could not explain. Researchers at UBC Okanagan have now identified the two enzymes responsible for building this molecule's distinctive twisted architecture, solving a long-standing mystery in plant biochemistry. The discovery matters not only as an answer to how nature works, but as a doorway toward producing powerful medicines sustainably, without depleting the rare species that carry them.
- A decades-old gap in our understanding of plant chemistry has finally closed — scientists now know the precise enzymatic steps that produce mitraphylline, a molecule long recognized for its therapeutic potential but never fully explained.
- The compound exists only in frustratingly small traces within tropical trees, making it nearly impossible to harvest or synthesize at the quantities needed for serious pharmaceutical research.
- A doctoral student's investigation revealed two enzymes working in sequence — one shaping the molecule's three-dimensional form, the other completing its transformation — like discovering the missing stations on a molecular assembly line.
- The enzymatic blueprint now enables a green chemistry approach: producing mitraphylline and related compounds at scale without harvesting rare tropical plants, shifting the work from extraction to engineering.
- Collaborative research spanning UBC Okanagan and the University of Florida, backed by Canadian and American scientific funding, positions this discovery as a foundation for developing an entirely new class of plant-derived medicines.
Deep in tropical forests, certain plants have long performed a chemical feat that science struggled to decode. They were quietly building mitraphylline — a rare molecule with anti-tumor and anti-inflammatory potential — but the molecular recipe remained hidden. This spring, researchers at UBC Okanagan published a discovery that finally cracks that code: two enzymes, working in sequence, are responsible for constructing the compound's distinctive twisted structure.
Mitraphylline belongs to a family of plant chemicals called spirooxindole alkaloids, defined by their complex ring architecture and potent biological effects. The problem was always scarcity — the compound appears only in trace amounts in tropical trees like kratom and cat's claw, both members of the coffee family, making isolation for research or medicine costly and difficult.
The breakthrough built on earlier work from Dr. Thu-Thuy Dang's lab, which in 2023 identified the first plant enzyme capable of creating the spiro molecular shape. Doctoral student Tuan-Anh Nguyen then led research uncovering the full two-enzyme sequence: the first positions the molecule into the correct three-dimensional form, the second completes its transformation into mitraphylline. Dang described it as finding the missing links in an assembly line — not just answering how nature builds these molecules, but revealing how to replicate the process.
The implications reach well beyond this single compound. With the enzymatic pathway now understood, researchers have a blueprint for sustainable production — what Nguyen calls a green chemistry approach — freeing pharmaceutical development from dependence on rare tropical species. Dang's next steps will focus on adapting these molecular tools to generate a broader range of therapeutic compounds, guided by the conviction that plants, as she put it, are fantastic natural chemists whose methods may yet unlock medicines we haven't imagined.
Deep in the tropical canopy, certain plants have been quietly performing a chemical feat that scientists struggled to understand for decades. They were building mitraphylline—a rare molecule with the potential to fight cancer—but the exact recipe remained hidden. Now researchers at UBC Okanagan have cracked the code, identifying the two enzymes plants use to construct this compound's distinctive twisted structure. The discovery, published this spring, doesn't just answer a long-standing question in plant chemistry. It opens a practical path toward producing the molecule sustainably, without stripping rare tropical species.
Mitraphylline belongs to an unusual family of plant chemicals called spirooxindole alkaloids, molecules defined by their twisted ring architecture and their potent biological effects. Scientists have known for years that these compounds possess anti-inflammatory and anti-tumor properties. What they didn't know was how plants actually made them—the molecular steps, the sequence, the machinery involved. The compound appears only in trace amounts in tropical trees like kratom and cat's claw, both members of the coffee family, which meant that isolating enough mitraphylline from nature for research or medicine was difficult and expensive.
The breakthrough began in 2023 when Dr. Thu-Thuy Dang's team at UBC Okanagan's Irving K. Barber Faculty of Science identified the first known plant enzyme capable of twisting a molecule into the distinctive spiro shape. Building on that foundation, doctoral student Tuan-Anh Nguyen led research that uncovered two critical enzymes working in sequence. The first organizes the molecule into the correct three-dimensional structure. The second transforms it into mitraphylline itself. "This is similar to finding the missing links in an assembly line," Dang explained. "It answers a long-standing question about how nature builds these complex molecules and gives us a new way to replicate that process."
The practical implications are significant. Many promising natural compounds exist in such small quantities in plants that recreating them in laboratories has remained prohibitively difficult. Now that researchers understand the enzymatic pathway, they have a blueprint for producing mitraphylline through what Nguyen calls a "green chemistry approach"—methods that are sustainable and don't depend on harvesting rare tropical plants. The discovery emerged from collaboration between Dang's laboratory and Dr. Satya Nadakuduti's research group at the University of Florida, supported by funding from Canada's Natural Sciences and Engineering Research Council, the Canada Foundation for Innovation, the Michael Smith Health Research BC Scholar Program, and the U.S. Department of Agriculture's National Institute of Food and Agriculture.
For Nguyen, the experience of contributing to the breakthrough reflected something broader about the research environment at UBC Okanagan—a place where students and faculty work closely on problems with global reach. "Being part of the team that uncovered the enzymes behind spirooxindole compounds has been amazing," he said. Dang's next steps will focus on adapting these molecular tools to create a wider range of therapeutic compounds. The work suggests that plants, as she put it, are "fantastic natural chemists," and that understanding their methods opens doors to medicines we haven't yet imagined.
Notable Quotes
This is similar to finding the missing links in an assembly line. It answers a long-standing question about how nature builds these complex molecules and gives us a new way to replicate that process.— Dr. Thu-Thuy Dang, UBC Okanagan Principal's Research Chair in Natural Products Biotechnology
With this discovery, we have a green chemistry approach to accessing compounds with enormous pharmaceutical value.— Tuan-Anh Nguyen, doctoral student
The Hearth Conversation Another angle on the story
Why does it matter that we found these two enzymes? Couldn't we just synthesize mitraphylline chemically from scratch?
We could try, but it's enormously expensive and wasteful. The molecule has this twisted structure that's hard to build in a lab. Plants do it elegantly with enzymes. Now we can use those same enzymes—or engineer versions of them—to make the compound reliably and cheaply.
So this is about copying nature's recipe rather than inventing our own?
Exactly. And it's also about not destroying tropical forests to harvest trace amounts of a rare compound. If we can grow the enzymes in fermentation tanks, we can produce mitraphylline sustainably.
How long until this becomes a medicine people can actually take?
That's the longer journey. We've solved the production puzzle. Now comes testing for safety and efficacy in humans, which takes years. But without this enzyme discovery, we wouldn't even have enough compound to test.
What makes mitraphylline special compared to other anti-cancer compounds?
Its structure is unusual—that twisted ring system—which gives it biological properties other molecules don't have. And it comes from plants that have been used traditionally for centuries. Sometimes nature has already done the screening for us.
Could this approach work for other rare plant compounds?
That's the real hope. Once you understand how plants make one spirooxindole alkaloid, you have tools to understand others. This could unlock a whole class of therapeutic molecules.